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Background:  To evaluate the clinical efficacy of sitagliptin for reducing plasma glucose levels in Korean subjects with type 2 dia-
betes mellitus during a 14-week treatment period.
Methods:  Our study design involved the addition of 100 mg sitagliptin once-daily to three ongoing combination therapy regi-
mens and changing from glimepiride and metformin to sitagliptin and metformin. 
Results:  The addition of sitagliptin 100 mg/day produced a statistically significant reduction in mean HbA1c level (mean HbA1c 
reduction of 0.99±0.85%, P<0.01). In the group taking a combination of sitagliptin and metformin (n=143, initial mean HbA1c 
level=7.48%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 0.72±0.76% (P<0.01), 47±
65 mg/dL (P<0.01), and 15±44 mg/dL (P<0.01), respectively. In the group taking a combination of sitagliptin, glimepiride, and 
metformin (n=125, initial mean HbA1c level=8.42%), the reductions in HbA1c, 2-hour postprandial glucose, and fasting glu-
cose levels were 1.09±0.86% (P<0.01), 62±64 mg/dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the group taking a 
combination of sitagliptin, glimepiride, metformin, and α-glucosidase inhibitor (n=63, initial mean HbA1c level=9.19%), the 
reductions in HbA1c, 2-hour postprandial glucose, and fasting glucose levels were 1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), 
and 35±51 mg/dL (P<0.01), respectively. In the group that had previous hypoglycemic events and that changed from glimepiri-
de to sitagliptin, HbA1c level did not change but fasting glucose increased significantly (14±29 mg/dL, P<0.01).
Conclusion:  Sitagliptin combination therapy for 14 weeks significantly improved glycemic control and was well-tolerated in 
Korean subjects with type 2 diabetes mellitus.
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INTRODUCTION
Treatment with a single oral hypoglycemic agent (OHA) is of-
ten unsuccessful at achieving glycemic control in subjects with 
type 2 diabetes mellitus (T2DM) [1,2]. The UK Prospective 
Diabetes Study (UKPDS) clearly demonstrated that T2DM is 
a progressive disease. After three years of treatment, for exam-
ple, T2DM was adequately controlled with a single drug in only 
50% of subjects, while this percentage had decreased to 25% 
after nine years [1,3]. It appears that many T2DM subjects will 
require combination therapy and the addition of an OHA.
  Metformin is the most commonly used OHA, both as a 
monotherapy and in combination with other agents [4]. Met-
formin is a biguanide that acts primarily by lowering hepatic 
glucose production and may also improve insulin resistance 
[5,6]. Sulphonylureas improve blood glucose levels by stimu-
Original Article
http://dx.doi.org/10.4093/dmj.2011.35.4.411
pISSN 2233-6079 · eISSN 2233-6087412
Chung HS, et al.
Diabetes Metab J 2011;35:411-417 http://e-dmj.org
lating insulin secretion from pancreatic β-cells in a non-glu-
cose–dependent manner [7]. α-Glucosidase inhibitors slow 
the breakdown of disaccharides and other carbohydrates in 
the gut, delaying the absorption of monosaccharides (princi-
pally glucose and fructose) in the small intestine [8]. The most 
popular combination treatment is metformin and sulfonyl-
urea [3]. In cases of inadequate glycemic control in dual com-
bination therapy, α-glucosidase inhibitors may be added to this 
regimen. In this setting, the use of insulin is often the next 
therapeutic step. However, insulin requires parenteral admin-
istration, which many subjects find undesirable. Hence, there 
is a need for additional OHA options to improve the options 
for combination therapy.
  Sitagliptin is a once-daily, orally active, potent, and highly 
selective dipeptidyl peptidase-4 (DPP-4) inhibitor approved in 
many countries for the treatment of subjects with T2DM. DPP-
4 is an enzyme involved in the degradation of the intact (active) 
incretin hormones glucagon-like peptide-1 (GLP-1) and glu-
cose-dependent insulinotropic peptide (GIP) to inactive me-
tabolites. GLP-1 and GIP are released into circulation by the 
intestine in response to a meal, and both hormones increase 
glucose-dependent insulin secretion. In addition, GLP-1 sup-
presses glucagon release. By inhibiting the degradation of ac-
tive incretins, sitagliptin increases active incretin concentra-
tions, thereby enhancing their glucoregulatory effects [2,9-11]. 
Sitagliptin is licensed for the treatment of T2DM in combina-
tion with metformin and/or a sulphonylurea or with a peroxi-
some proliferator-activated receptor (PPARγ) agonist (thia-
zolidinediones) [12]. In this study, we looked at the efficacy and 
safety of adding 100 mg of sitagliptin to ongoing treatment with 
metformin alone, to a dual combination treatment of glimepiri-
de and metformin, or to a triple combination treatment of 
glimepiride, metformin, and acarbose in Korean subjects with 
T2DM. We also investigated the effect of changing from 
glimepiride and metformin to sitagliptin and metformin in 
patients that suffered recent hypoglycemic events.
METHODS
Subjects
This retrospective study involved a cohort of 598 subjects. We 
excluded 258 potential subjects because their medical history 
included steroids, surgery, hospitalization (for example for in-
fection), cancer, or because they had stopped taking OHAs. 
Inclusion criteria were: 1) male or female, aged 45 to 75 years; 
2) clinically diagnosed T2DM for at least six months; 3) ongo-
ing treatment with the same OHA for at least six months; 4) 
inadequately controlled T2DM (HbA1c 7.0% to 10.0% or 
HbA1c 5.5% to 7.5% in the case of changing from glimepiride 
to sitagliptin); and 5) no abnormal laboratory findings for as-
partate aminotransferase (AST), alanine aminotransferase 
(ALT), blood urea nitrogen (BUN), creatinine, or complete 
blood count (CBC). Laboratory data from 340 subjects were 
finally used for analysis. Data were collected from October 
2008 to August 2009 through review of medical records and 
via interview where possible.
Methods
We collected cases where sitagliptin (100 mg once-daily) had 
been added to one of three ongoing treatment regimens: a 
group taking metformin (mean dose 876 mg/day); a group 
taking glimepiride (mean dose 3.95 mg/day) and metformin 
(mean dose 956 mg/day); and a group taking glimepiride (mean 
dose 4.63 mg/day), metformin (mean dose 1,464 mg/day), and 
acarbose (mean dose 282 mg/day). We also collected the data 
of patients whose treatment changed from glimepiride (mean 
dose 3.44 mg/day) and metformin (mean dose 722 mg/day) to 
sitagliptin (mean dose 100 mg/day) and metformin. Before 
changing medication, patients had HbA1c levels in the 5.5% to 
7.5% range and had experienced a recent hypoglycemic event 
twice in the last month (SMBG or serum glucose level <70 
mg/dL, with or without hypoglycemic symptoms).
Statistical analysis
Data are reported as mean±standard deviation. All statistical 
computations were performed using the software program 
PASW version 17.0 (SPSS Inc., Chicago, IL, USA). Compari-
sons were made using paired t-test and one-way ANOVA. A 
paired t-test was used to compare parameters before and after 
the addition of sitagliptin. One-way ANOVA was used for ter-
tile analysis with baseline characteristics (C-peptide, age, and 
body mass index [BMI]) and changes in glucose. P values of 
less than 0.05 were considered statistically significant.
RESULTS
Baseline characteristics
The final analysis included 340 subjects (138 women, 202 men) 
divided according to treatment regimen into group 1 (metfor-
min alone, n=132/385), group 2 (glimepiride plus metformin 413
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combination therapy, n=135/385), group 3 (glimepiride plus 
metformin and acarbose or voglibose, n=73/385), and group 
4 (glimepiride plus metformin combination therapy and hy-
poglycemia, n=45/385). Baseline characteristics of the sub-
jects are summarized in Table 1. Before adding sitagliptin, the 
mean HbA1c level was 8.24±1.31%, the mean BMI was 25.6± 
3.6 kg/m
2 and the mean DM duration was 6.4 years. The mean 
duration of sitagliptin therapy was 14±4 weeks. Subjects in 
group 3 had the highest mean values for HbA1c, fasting plas-
ma glucose (FPG), and 2-hour postprandial glucose (2h-PPG). 
Efficacy
In the overall study (groups 1, 2, 3), treatment with 100 mg si-
tagliptin once daily significantly decreased HbA1c, FPG, and 
2h-PPG values from baseline (mean HbA1c change -0.99± 
0.85%, P<0.01; mean FPG change -25±49 mg/dL, P<0.01; 
mean 2h-PPG change -58±65 mg/dL, P<0.01). The addition 
of sitagliptin also led to significant improvements in HbA1c, 
FPG, and 2h-PPG in each group. In the combination group 
taking sitagliptin and metformin (group 1: n=132, initial mean 
HbA1c=7.48%), the reductions in HbA1c, 2h-PPG, and FPG 
levels were 0.72±0.76% (P<0.01), 47±65 mg/dL (P<0.01), and 
15±44 mg/dL (P<0.01), respectively. In the combination group 
of sitagliptin, sulfonylurea, and biguanide (group 2: n=135, 
initial mean HbA1c=8.42%), the reductions in HbA1c, 2h-
PPG, and FPG levels were 1.09±0.86% (P<0.01), 62±64 mg/
dL (P<0.01), and 31±45 mg/dL (P<0.01), respectively. In the 
combination group of sitagliptin, sulfonylurea, biguanide, and 
α-glucosidase inhibitor (group 3: n=73, initial mean HbA1c=
9.19%), the reductions in HbA1c, 2h-PPG, and FPG levels were 
1.27±0.70% (P<0.01), 72±65 mg/dL (P<0.01), and 35±51 mg/
dL (P<0.01), respectively (Table 2).
  We also analyzed the group whose medication was changed 
from glimepiride and metformin to sitagliptin and metformin 
(group 4). A majority of the group experienced an improve-
ment in hypoglycemic events (71%, 32/45). No significant 
Table 1.  Baseline characteristics
Characteristic
Group 1+2+3
(n=340)
Group 1  
(metformin only)  
(n=132)
Group 2  
(metformin+ 
glimepiride)  
(n=135)
Group 3 
(metformin+ 
glimepiride 
+acarbose)  
(n=73)
Group 4 
(substitute sitagliptin 
for glimepiride) 
(n=45)
Gender, M/F 202/138 77/55 75/60 50/23 26/19
Age, yr 59.2±10.9 56.2±7.6 59.4±8.8 64.3±5.7 55.3±8.1
BMI, kg/m
2 25.6±3.6 24.8±2.1 25.5±1.9 27.2±3.1 24.6±2.8
Duration of diabetes, yr 6.4±3.1 5.3±2.1 6.6±2.7 8.0±2.1 4.2±1.9
HbA1c, % 8.24±1.31 7.48±1.00 8.42±1.13 9.19±1.08 6.65±0.38
FPG, mg/dL 168±45 150±35 170±44 197±48 97±23
Post prandial glucose,  
mg/dL
261.0±71 228±53 276±70 293±68 145±34
C-peptide, ng/mL 2.53±1.14 2.82±1.01 2.64±0.85 1.79±0.93 3.12±1.51
ALT, U/L 28.3±16.2 28.2±11.7 24.1±12.6 36.2±8.2 25.3±11.3
AST, U/L 24.7±12.0 24.9±8.3 23.4±10.1 26.7±9.4 25±11.1
BUN, mg/dL 16.5±5.0 16.8±4.6 16.4±2.3 16.1±3.1 15.3±2.1
Creatinine, mg/dL 0.91±0.20 0.92±0.12 0.90±0.11 0.89±0.11 0.87±0.11
Total cholesterol, mg/dL 172.7±36.7 171.3±24.3 174.1±21.5 172.6±31.4 170.1±24.7
Triglycerides, mg/dL 177.9±125.2 177.4±115.7 178.2±107.1 178.2±100.8 168±99.8
HDL-C, mg/dL 45.9±11.0 46.1±4.7 45.5±8.7 46.3±11.9 45.6±10.1
LDL-C, mg/dL 101.4±30.0 100.3±23.1 102.5±24.8 101.4±21.3 100.6±11.4
Data are presented as mean±standard deviation.
BMI, body mass index; FPG, fasting plasma glucose; AST, aspartate aminotransferase; ALT, alanine aminotransferase; BUN, blood urea nitro-
gen; HDL-C, high density lipoprotein cholesterol; LDL-C, low density lipoprotein cholesterol.414
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change was observed in HbA1c or 2h-PPG level; however, FPG 
increased significantly (14±29 mg/dL, P<0.01) (Table 2). If 
we defined a target HbA1c response level as less than 7.0%, the 
incidence of responders was 82% (108/132), 38% (51/135), and 
15% (11/73) for groups 1, 2, and 3, respectively. If we defined 
an HbA1c response as a reduction of more than 1%, the inci-
dence of responders was 32% (42/132), 47% (64/135), and 47% 
(34/73) for groups 1, 2, and 3 (initial HbA1c levels: group 1, 
7.48%; group 2, 8.42%; group 3, 9.19%). We analyzed the dif-
ferences between responders (HbA1c<7.0% or HbA1c reduced 
more than 1%) and non-responders but found no significant 
factors among initial c-peptide, DM duration, initial weight 
and initial BMI.
  Treatment with sitagliptin significantly improved fasting c-
peptide values for all study groups (Fig. 1). Sitagliptin had a 
neutral effect on plasma lipid level relative to baseline labora-
tory data (data not shown). We divided the study participants 
into three groups based on initial fasting C-peptide value: C-
peptide<2.27 ng/mL; 2.27 ng/mL≤C-peptide<3.3 ng/mL; 
and C-peptide≥3.3 ng/mL. After 14 weeks of treatment, we 
did not observe any significant differences in HbA1c, FPG, or 
2h-PPG levels between the tertiles (Fig. 2). 
  BMI, age, and sex were not independent predictors of re-
sponse to sitagliptin (Fig. 3). Body weight decreased insignifi-
cantly in all treatment groups (groups 1, 2, 3, 4), and we in-
ferred that this result differed from those of other studies be-
cause of our short study period (Table 2).
Safety
Sitagliptin was generally well-tolerated in this study, resulting 
in a 9.2% incidence of gastrointestinal trouble. Sitagliptin did 
not have to be discontinued because of gastrointestinal trouble 
since the symptoms were mild (diarrhea and abdominal dis-
tension). Addition of sitagliptin to an existing treatment re-
sulted in a 0.8% incidence of hypoglycemia. Hypoglycemic 
events resulted in discontinuation of treatment in one study 
participant. We did not observe any other clinically significant 
changes in vital signs or laboratory findings in the study groups.
DISCUSSION
In this study, the addition of once daily sitagliptin led to clini-
cally meaningful reductions in HbA1c, FPG, and 2h-PPG lev-
Table 2.  Changes in HbA1c, FPG, 2h-PPG, and weight according to addition of sitagliptin to existing medication and substitut-
ing sitagliptin for sulfonylurea
Group ∆HbA1c, % ∆FPG, mg/dL ∆2h-PPG, mg/dL ∆Wt, kg
Group 1 
metformin+sitagliptin (n=132)
-0.72±0.76
a
(P<0.01)
-15±44
a
(P<0.01) 
-47±65
a
(P<0.01) 
-1.00±10.04
(P=0.28)
Group 2 
glimepiride, metformin+sitagliptin (n=135)
-1.09±0.86
a
(P<0.01) 
-31±45
a
(P<0.01) 
-62±64
a
(P<0.01) 
-0.82±8.11
(P=0.28)
Group 3 
glimepiride, metformin, α-glucosidase inhibitor+sitagliptin 
(n=73)
-1.27±0.70
a
(P<0.01) 
-35±51
a
(P<0.01) 
-72±65
a
(P<0.01) 
-2.00±16.51
(P=0.44)
Group 4 
glimepiride & metformin→sitagliptin & metformin (n=45)
0.06±0.73
(P=0.53)
14±29
a
(P<0.01)
10±57
(P=0.25)
-1.08±12.21
(P=0.35)
Paired t-test.
∆, (after adding or substituting sitagliptin)–(before adding or substituting sitagliptin); FPG, fasting plasma glucose; 2h-PPG, 2 hour-postpran-
dial glucose. 
aP value<0.05. 
Fig. 1.  Fasting C-peptide values after 14-weeks of addition of 
sitagliptin increased significantly from baseline (P<0.01). 
Paired t-test, 
aP value <0.01. 
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els in Korean subjects with T2DM with inadequate glycemic 
control with previous medications (HbA1c 7.0% to 10.0%). 
Compared to a previous multi-national study by Scott et al. [13], 
the reduction in HbA1c was similar in the sitagliptin and met-
formin combination group (HbA1c change, -0.72% vs. -0.73%). 
  In both the sitagliptin, sulfonylurea, and biguanide combi-
nation group (group 2: n=135, initial mean HbA1c=8.42%) 
and the sitagliptin, sulfonylurea, biguanide, and α-glucosidase 
inhibitor combination group (group 3: n=73, initial mean 
HbA1c=9.19%), the reductions in HbA1c, 2h-PPG, and FPG 
levels were significant. It was known that the higher was the 
initial level of HbA1c, the greater was the reduction in HbA1c 
level with the same medication. Although the initial levels of 
HbA1c, 2h-PPG, and FPG were higher in the multiple drug 
combination group compared to those in the sitagliptin and 
metformin group, this did not result in inferior reductions in 
the glucose levels of multidrug groups compared to that in the 
sitagliptin and metformin group (group 1: n=132, initial mean 
HbA1c=7.48%). The group that changed from glimepiride to 
sitagliptin and that previously had a hypoglycemic event, 
HbA1c did not increase but fasting glucose increased. In addi-
tion, the incidence of hypoglycemic events decreased. Chang-
ing from glimepiride to sitagliptin should therefore be consid-
ered for patients with recurrent fasting hypoglycemia and 
HbA1c levels relatively close to target due to glimepiride and 
metformin treatment.
  The incidences of hypoglycemia, gastrointestinal troubles, 
and other side effects were low. In contrast to other studies, the 
tertile analysis of fasting c-peptide and BMI showed no corre-
lation with reduction in HbA1c; however, it should be noted 
that the initial C-peptide levels in this study were greater than 
1.0 ng/mL.
  Treatment with sitagliptin improved fasting c-peptide lev-
els. T2DM arises primarily from dysfunctional pancreatic 
β-cells rather than from impaired insulin sensitivity [14,15]. 
Typically, islet function has already declined by approximately 
50% by the time a subject is diagnosed with T2DM [14]. Re-
duced pancreatic β-cell mass, largely because of accelerated 
apoptosis [15], seems to at least partially account for impaired 
islet function. Sulphonylureas also improve blood glucose lev-
Fig. 2.  Changes in HbA1c, fasting plasma glucose (FPG), and 2 hour-postprandial glucose (2h-PPG) values according to base-
line C-peptide values were insignificant. (A) Changes in HbA1c according to baseline C-peptide. (B) Changes in FPG according 
to baseline C-peptide. (C) Changes in 2h-PPG according to baseline C-peptide. One-way ANOVA. 
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els by stimulating insulin secretion; however, some kinds of 
sulphonylureas have been shown to induce apoptosis in a 
dose- and time-dependent manner in β-cell lines and islets of 
humans and rodents [16]. Reportedly, DPP-4 inhibitor in-
creases β-cell differentiation and proliferation, enhances islet 
architecture remodeling, and preserves islet function in dia-
betic mice [17]. Experimental and clinical studies suggest that 
DPP-4 inhibitors could preserve, and possibly reverse, the 
progressive elimination of pancreatic β-cells and the loss of in-
sulin secretory capacity characteristic of T2DM [18]. Howev-
er, long-term studies in subjects with T2DM are needed to 
demonstrate the clinical significance of these findings.
  We note that our retrospective study has some limitations. 
First, we could not confirm that the prescribed lifestyle modi-
fications involving changes in diet or exercise were performed 
by the participants. Second, medical compliance by the en-
rolled patients was not guaranteed. Third, because data were 
obtained through review of medical records, information of 
hypoglycemic events or the incidence of gastrointestinal trou-
ble could have been omitted.
  In the Korean population, most subjects with T2DM are not 
obese and have a relatively low volume density of pancreatic 
β-cell mass [19]. Our study is important because the effects of 
OHAs in Korean subjects are not the same as those seen in 
Western subjects, and because few studies have been conduct-
ed on the effects of sitagliptin in Korean subjects. Additional 
long-term studies in Korean subjects with T2DM are needed. 
  In summary, this study shows that treatment with 100 mg 
sitagliptin once daily appears to be effective and well tolerated 
in Korean subjects with T2DM who experience inadequate 
glycemic control with metformin alone, with a combination of 
glimepiride and metformin, or with a combination of glimepiri-
de, metformin, and acarbose. Treatment with sitagliptin also 
appears to improve fasting c-peptide values in these subjects.
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